Klaria Pharma Holding AB (publ.) (STO:KLAR)
Sweden
· Delayed Price · Currency is SEK 0.790
-0.010 (-1.25%)
Mar 9, 2026, 5:23 PM CET
Klaria Pharma Holding AB (publ.) Company Description
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock.
Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection.
The company is also involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.
Klaria Pharma Holding AB (publ.)
| Country | Sweden |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Scott Boyer |
Contact Details
Address: Virdings Allé 2 Uppsala, 754 50 Sweden | |
| Phone | 46 84 46 42 99 |
| Website | klaria.com |
Stock Details
| Ticker Symbol | KLAR |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007280326 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott Boyer | Chief Executive Officer and Director |
| Hans Richter | Chief Financial Officer |
| Marc Willuhn Ph.D. | Head of Chemistry, Manufacturing and Control |
| Dr. Hans Olivecrona M.D., Ph.D. | Chief Medical Officer |